全球阿兹海默症生物标记市场规模、份额、趋势和成长分析报告（2026-2034）

阿兹海默症生物标记市场预计将从 2025 年的 15.9 亿美元成长到 2034 年的 35.6 亿美元，2026 年至 2034 年的复合年增长率为 9.35%。

由于阿兹海默症和其他神经退化性疾病的盛行率不断上升，全球阿兹海默症生物标记市场正在成长。全球人口老化是推动早期精准诊断需求的主要因素。生物标记在疾病早期检测中发挥着至关重要的作用，有助于制定更有效的治疗方案和疾病管理。对早期诊断日益增长的关注正在推动市场成长。

神经病学领域的研究和开发活动正在加速新产物标记的发现。影像技术、脑脊髓液检测和血液生物标记检测等方面的技术进步提高了诊断的准确性。政府对失智症研究的资助和支持也促进了市场扩张。製药公司在药物研发和临床试验中越来越依赖生物标记。

未来几年，无创且经济高效的诊断测试的发展预计将惠及市场。基于血液的生物标记因其便利性而备受关注。人们对大脑健康的日益重视以及对个人化医疗投入的增加将进一步推动市场需求。随着阿兹海默症新治疗方法的出现，生物标记检测将变得更加重要。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球阿兹海默症生物标记市场：依生物标记类型划分

• 市场分析、洞察与预测
• 脑脊髓液生物标记
• β-淀粉样蛋白
• Tau蛋白
• 基因生物标记
• 载脂蛋白E
• 血液生物标记
• 其他的

第五章 全球阿兹海默症生物标记市场：依检测技术划分

• 市场分析、洞察与预测
• 分子诊断
• 免疫检测

第六章 全球阿兹海默症生物标记市场：依最终用户划分

• 市场分析、洞察与预测
• 医院和诊所
• 诊断检查室
• 研究机构和学术中心
• 其他的

第七章 全球阿兹海默症生物标记市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Enzo Life Sciences Inc
  • Thermo Fisher Scientific Inc
  • AnaSpec Inc
  • Merck KGaA
  • Cell Signaling Technology Inc
  • Fujirebio
  • Imagilys
  • NanoSomiX
  • QIAGEN
  • 23andMe Inc
  • Quanterix
  • C2N Diagnostics
  • Quest Diagnostics

The Alzheimer's Disease Biomarkers Market size is expected to reach USD 3.56 Billion in 2034 from USD 1.59 Billion (2025) growing at a CAGR of 9.35% during 2026-2034.

The Global Alzheimer's Disease Biomarkers Market is growing due to the increasing prevalence of Alzheimer's disease and other neurodegenerative disorders. The aging global population is a key factor driving the need for early and accurate diagnosis. Biomarkers play an important role in detecting the disease at an early stage, which helps in better treatment planning and disease management. This rising focus on early diagnosis is supporting market growth.

Research and development activities in neurology are accelerating the discovery of new biomarkers. Technological advancements in imaging techniques, cerebrospinal fluid testing, and blood-based biomarker tests are improving diagnostic accuracy. Government funding and support for dementia research are also contributing to market expansion. Pharmaceutical companies are increasingly relying on biomarkers for drug development and clinical trials.

In the coming years, the market is expected to benefit from the development of non-invasive and cost-effective diagnostic tests. Blood-based biomarkers are likely to gain significant attention due to their convenience. Growing awareness about brain health and increasing investments in personalized medicine will further boost demand. As new therapies for Alzheimer's emerge, biomarker testing will become even more essential.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type Of Biomarker

• CSF Biomarkers
• Amyloid Beta
• Tau Protein
• Genetic Biomarkers
• Apolipoprotein E
• Blood Biomarkers
• Others

By Detection Technique

• Molecular Diagnostics
• Immunoassays

By End-User

• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes and Academic Centers
• Others

COMPANIES PROFILED

• Enzo Life Sciences Inc, Thermo Fisher Scientific Inc, AnaSpec Inc, Merck KGaA, Cell Signaling Technology Inc, Fujirebio, Imagilys, NanoSomiX, QIAGEN, 23andMe Inc, Quanterix, C2N Diagnostics, Quest Diagnostics
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY TYPE OF BIOMARKER 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Biomarker
• 4.2. CSF Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Amyloid Beta Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Tau Protein Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Genetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Apolipoprotein E Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Blood Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY DETECTION TECHNIQUE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Detection Technique
• 5.2. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immunoassays Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Research Institutes and Academic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type Of Biomarker
  • 7.2.2 By Detection Technique
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type Of Biomarker
  • 7.3.2 By Detection Technique
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type Of Biomarker
  • 7.4.2 By Detection Technique
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type Of Biomarker
  • 7.5.2 By Detection Technique
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type Of Biomarker
  • 7.6.2 By Detection Technique
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ALZHEIMER'S DISEASE BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Enzo Life Sciences Inc
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 AnaSpec Inc
  • 9.2.4 Merck KGaA
  • 9.2.5 Cell Signaling Technology Inc
  • 9.2.6 Fujirebio
  • 9.2.7 Imagilys
  • 9.2.8 NanoSomiX
  • 9.2.9 QIAGEN
  • 9.2.10 23andMe Inc
  • 9.2.11 Quanterix
  • 9.2.12 C2N Diagnostics
  • 9.2.13 Quest Diagnostics